Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2012, Article ID 751629, 9 pages
http://dx.doi.org/10.1155/2012/751629
Research Article

A Picrorhiza kurroa Derivative, Picroliv, Attenuates the Development of Dextran-Sulfate-Sodium-Induced Colitis in Mice

1Department of Gastroenterology, The Second Hospital, Lanzhou University, Gansu Province, Lanzhou 730000, China
2Key Laboratory of Digestive System Tumors, Gansu Province, Lanzhou 730000, China

Received 8 April 2012; Revised 23 August 2012; Accepted 6 September 2012

Academic Editor: Julio Galvez

Copyright © 2012 De-Kui Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Fiocchi, “Inflammatory bowel disease: etiology and pathogenesis,” Gastroenterology, vol. 115, no. 1, pp. 182–205, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. D. K. Podolsky, “Inflammatory bowel disease,” New England Journal of Medicine, vol. 347, no. 6, pp. 417–429, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. B. E. Sands, “Therapy of inflammatory bowel disease,” Gastroenterology, vol. 118, no. 2, pp. S68–S82, 2000. View at Google Scholar · View at Scopus
  4. W. J. Sandborn and S. R. Targan, “Biologic therapy of inflammatory bowel disease,” Gastroenterology, vol. 122, no. 6, pp. 1592–1608, 2002. View at Google Scholar · View at Scopus
  5. S. Ardizzone and G. B. Porro, “Biologic therapy for inflammatory bowel disease,” Drugs, vol. 65, no. 16, pp. 2253–2286, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. J. G. Reddy and E. V. Loftus Jr., “Safety of infliximab and other biologic agents in the inflammatory bowel diseases,” Gastroenterology Clinics of North America, vol. 35, no. 4, pp. 837–855, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. K. A. Papadakis and S. R. Targan, “Role of cytokines in the pathogenesis of inflammatory bowel disease,” Annual Review of Medicine, vol. 51, pp. 289–298, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Rogler and T. Andus, “Cytokines in inflammatory bowel disease,” World Journal of Surgery, vol. 22, no. 4, pp. 382–389, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Ogata and T. Hibi, “Cytokine and anti-cytokine therapies for inflammatory bowel disease,” Current Pharmaceutical Design, vol. 9, no. 14, pp. 1107–1113, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Nakamura, K. Honda, T. Mizutani, H. Akiho, and N. Harada, “Novel strategies for the treatment of inflammatory bowel disease: selective inhibition of cytokines and adhesion molecules,” World Journal of Gastroenterology, vol. 12, no. 29, pp. 4628–4635, 2006. View at Google Scholar · View at Scopus
  11. J. Y. Xiang, L. G. Wu, X. L. Huang et al., “Amelioration of murine dextran sulfate sodium-induced colitis by nuclear factor-κb decoy oligonucleotides,” American Journal of Surgery, vol. 197, no. 6, pp. 797–805, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Najafzadeh, P. D. Reynolds, A. Baumgartner, D. Jerwood, and D. Anderson, “Chaga mushroom extract inhibits oxidative DNA damage in lymphocytes of patients with inflammatory bowel disease,” BioFactors, vol. 31, no. 3-4, pp. 191–200, 2007. View at Google Scholar · View at Scopus
  13. A. Roessner, D. Kuester, P. Malfertheiner, and R. Schneider-Stock, “Oxidative stress in ulcerative colitis-associated carcinogenesis,” Pathology Research and Practice, vol. 204, no. 7, pp. 511–524, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Dost, H. Ozkayran, F. Gokalp, C. Yenisey, and M. Birincioglu, “The effect of Hypericum perforatum (St. John's Wort) on experimental colitis in rat,” Digestive Diseases and Sciences, vol. 54, no. 6, pp. 1214–1221, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. A. Te Velde, I. Pronk, F. De Kort, and P. C. F. Stokkers, “Glutathione peroxidase 2 and aquaporin 8 as new markers for colonic inflammation in experimental colitis and inflammatory bowel diseases: an important role for H2O2?” European Journal of Gastroenterology and Hepatology, vol. 20, no. 6, pp. 555–560, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. A. S. Baldwin Jr., “Series introduction: the transcription factor NF-κB and human disease,” Journal of Clinical Investigation, vol. 107, pp. 3–6, 2001. View at Google Scholar
  17. C. Jobin and R. Balfour Sartor, “NF-κB signaling proteins as therapeutic targets for inflammatory bowel diseases,” Inflammatory Bowel Diseases, vol. 6, no. 3, pp. 206–213, 2000. View at Google Scholar · View at Scopus
  18. J. N. Glasgow, T. Wood, and J. R. Perez-Polo, “Identification and characterization of nuclear factor κB binding sites in the murine bcl-x promoter,” Journal of Neurochemistry, vol. 75, no. 4, pp. 1377–1389, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. P. P. Tak and G. S. Firestein, “NF-κB: a key role in inflammatory diseases,” Journal of Clinical Investigation, vol. 107, pp. 7–11, 2001. View at Google Scholar
  20. S. Ghosh, M. J. May, and E. B. Kopp, “NF-κB and rel proteins: evolutionarily conserved mediators of immune responses,” Annual Review of Immunology, vol. 16, pp. 225–260, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Schreiber, S. Nikolaus, and J. Hampe, “Activation of nuclear factor κB inflammatory bowel disease,” Gut, vol. 42, no. 4, pp. 477–484, 1998. View at Google Scholar · View at Scopus
  22. G. Rogler, K. Brand, D. Vogl et al., “Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa,” Gastroenterology, vol. 115, no. 2, pp. 357–369, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. M. F. Neurath, S. Pettersson, K. H. Meyer Zum Buschenfelde, and W. Strober, “Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice,” Nature Medicine, vol. 2, no. 9, pp. 998–1004, 1996. View at Publisher · View at Google Scholar · View at Scopus
  24. M. F. Neurath and S. Pettersson, “Predominant role of NF-κB p65 in the pathogenesis of chronic intestinal inflammation,” Immunobiology, vol. 198, no. 1–3, pp. 91–98, 1997. View at Google Scholar · View at Scopus
  25. R. Mehrotra, S. Rawat, D. K. Kulshreshtha, G. K. Patnaik, and B. N. Dhawan, “In vitro studies on the effect of certain natural products against hepatitis B virus,” Indian Journal of Medical Research Section B, vol. 92, pp. 133–138, 1990. View at Google Scholar · View at Scopus
  26. C. C. Baruah, P. P. Gupta, A. Nath, L. G. K. Patnaik, and B. N. Dhawan, “Anti-allergic and anti-anaphylactic activity of picroliv—a standardised iridoid glycoside fraction of Picrorhiza kurroa,” Pharmacological Research, vol. 38, no. 6, pp. 487–492, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Rastogi, A. K. Srivastava, M. Srivastava, and A. K. Rastogi, “Hepatocurative effect of picroliv and silymarin against aflatoxin B1 induced hepatotoxicity in rats,” Planta Medica, vol. 66, no. 8, pp. 709–713, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Rastogi, A. K. Srivastava, and A. K. Rastogi, “Long term effect of aflatoxin B1 on lipid peroxidation in rat liver and kidney: effect of picroliv and silymarin,” Phytotherapy Research, vol. 15, no. 4, pp. 307–310, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Rastogi, A. K. Srivastava, and A. K. Rastogi, “Biochemical changes induced in liver and serum of aflatoxin B1-treated male Wistar rats: preventive effect of Picroliv,” Pharmacology and Toxicology, vol. 88, no. 2, pp. 53–58, 2001. View at Google Scholar · View at Scopus
  30. B. Saraswat, P. K. S. Visen, G. K. Patnaik, and B. N. Dhawan, “Protective effect of picroliv, active constituent of Picrorhiza kurrooa, against oxytetracycline induced hepatic damage,” Indian Journal of Experimental Biology, vol. 35, no. 12, pp. 1302–1305, 1997. View at Google Scholar · View at Scopus
  31. A. Santra, S. Das, A. Maity, S. B. Rao, and D. N. G. Mazumder, “Prevention of carbon tetrachloride-induced hepatic injury in mice by Picrorhiza kurrooa,” Indian Journal of Gastroenterology, vol. 17, no. 1, pp. 6–9, 1998. View at Google Scholar · View at Scopus
  32. C. Girish and S. C. Pradhan, “Hepatoprotective activities of picroliv, curcumin, and ellagic acid compared to silymarin on carbon-tetrachloride-induced liver toxicity in mice,” Journal of Pharmacology and Pharmacotherapeutics, vol. 3, no. 2, pp. 149–155, 2012. View at Google Scholar
  33. C. Girish, B. C. Koner, S. Jayanthi, K. Ramachandra Rao, B. Rajesh, and S. C. Pradhan, “Hepatoprotective activity of picroliv, curcumin and ellagic acid compared to silymarin on paracetamol induced liver toxicity in mice,” Fundamental and Clinical Pharmacology, vol. 23, no. 6, pp. 735–745, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Rastogi, S. Saksena, N. K. Garg, N. K. Kapoor, D. P. Agarwal, and B. N. Dhawan, “Picroliv protects against alcohol-induced chronic hepatotoxicity in rats,” Planta Medica, vol. 62, no. 3, pp. 283–285, 1996. View at Publisher · View at Google Scholar · View at Scopus
  35. A. K. Singh, H. Mani, P. Seth et al., “Picroliv preconditioning protects the rat liver against ischemia-reperfusion injury,” European Journal of Pharmacology, vol. 395, no. 3, pp. 229–239, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Seth, R. Kumari, S. Madhavan et al., “Prevention of renal ischemia-reperfusion-induced injury in rats by picroliv,” Biochemical Pharmacology, vol. 59, no. 10, pp. 1315–1322, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. Q. Jia, M. F. Hong, and D. Minter, “Pikuroside: a novel iridoid from Picrorhiza kurroa,” Journal of Natural Products, vol. 62, no. 6, pp. 901–903, 1999. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Sinha, J. Mehrotra, L. Bala, A. K. Jaiswal, and B. N. Dhawan, “Picroliv, the iridoid glycoside fraction of Picrorhiza kurroa, selectively augments human T cell response to mycobacterial protein antigens,” Immunopharmacology and Immunotoxicology, vol. 20, no. 4, pp. 579–588, 1998. View at Google Scholar · View at Scopus
  39. N. Shakya, S. A. Sane, and S. Gupta, “Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulator—picroliv,” Parasitology Research, vol. 108, no. 4, pp. 793–800, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. K. J. Jeena, K. L. Joy, and R. Kuttan, “Effect of Emblica officinalis, Phyllanthus amarus and Picrorrhiza kurroa on N-nitrosodiethylamine induced hepatocarcinogenesis,” Cancer Letters, vol. 136, no. 1, pp. 11–16, 1999. View at Publisher · View at Google Scholar · View at Scopus
  41. N. V. Rajeshkumar and R. Kuttan, “Inhibition of N-nitrosodiethylamine—induced hepatocarcinogenesis by Picroliv,” Journal of Experimental and Clinical Cancer Research, vol. 19, no. 4, pp. 459–465, 2000. View at Google Scholar · View at Scopus
  42. N. V. Rajeshkumar and R. Kuttan, “Protective effect of Picroliv, the active constituent of Picrorhiza kurroa, against chemical carcinogenesis in mice,” Teratogenesis Carcinogenesis and Mutagenesis, vol. 21, no. 4, pp. 303–313, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. N. V. Rajeshkumar and R. Kuttan, “Modulation of carcinogenic response and antioxidant enzymes of rats administered with 1,2-dimethylhydrazine by Picroliv,” Cancer Letters, vol. 191, no. 2, pp. 137–143, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Chander, N. K. Kapoor, and B. N. Dhawan, “Picroliv, picroside-I and kutkoside from Picrorhiza kurrooa are scavengers of superoxide anions,” Biochemical Pharmacology, vol. 44, no. 1, pp. 180–183, 1992. View at Publisher · View at Google Scholar · View at Scopus
  45. P. Seth, S. V. Sundar, R. K. Seth et al., “Picroliv modulates antioxidant status and down-regulates AP1 transcription factor after hemorrhage and resuscitation,” Shock, vol. 19, no. 2, pp. 169–175, 2003. View at Google Scholar · View at Scopus
  46. J. P. Gaddipati, S. Madhavan, G. S. Sidhu, A. K. Singh, P. Seth, and R. K. Maheshwari, “Picroliv—a natural product protects cells and regulates the gene expression during hypoxia/reoxygenation,” Molecular and Cellular Biochemistry, vol. 194, no. 1-2, pp. 271–281, 1999. View at Publisher · View at Google Scholar · View at Scopus
  47. P. Anand, A. B. Kunnumakkara, K. B. Harikumar, S. A. Kwang, V. Badmaev, and B. B. Aggarwal, “Modification of cysteine residue in p65 subunit of nuclear factor-κB (NF-κB) by picroliv suppresses NF-κB-regulated gene products and potentiates apoptosis,” Cancer Research, vol. 68, no. 21, pp. 8861–8870, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. N. Mittal, N. Gupta, S. Saksena, N. Goyal, U. Roy, and A. K. Rastogi, “Protective effect of Picroliv from Picrorhiza kurroa against Leishmania donovani infections in Mesocricetus auratus,” Life Sciences, vol. 63, no. 20, pp. 1823–1834, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. S. N. S. Murthy, H. S. Cooper, H. Shim, R. S. Shah, S. A. Ibrahim, and D. J. Sedergran, “Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin,” Digestive Diseases and Sciences, vol. 38, no. 9, pp. 1722–1734, 1993. View at Google Scholar · View at Scopus
  50. T. Ten Hove, B. Van den Blink, I. Pronk, P. Drillenburg, M. P. Peppelenbosch, and S. J. H. Van Deventer, “Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis,” Gut, vol. 50, no. 4, pp. 507–512, 2002. View at Publisher · View at Google Scholar · View at Scopus
  51. A. R. Martín, I. Villegas, M. Sánchez-Hidalgo, and C. A. De La Lastra, “The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model,” British Journal of Pharmacology, vol. 147, no. 8, pp. 873–885, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Kurtovic and I. Segal, “Recent advances in biological therapy for inflammatory bowel disease,” Tropical Gastroenterology, vol. 25, no. 1, pp. 9–14, 2004. View at Google Scholar · View at Scopus
  53. C. Thukral, A. Cheifetz, and M. A. Peppercorn, “Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date,” Drugs, vol. 66, no. 16, pp. 2059–2065, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. F. N. Aberra and G. R. Lichtenstein, “Infliximab in ulcerative colitis,” Gastroenterology Clinics of North America, vol. 35, no. 4, pp. 821–836, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. B. G. Feagan, W. Reinisch, P. Rutgeerts et al., “The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients,” American Journal of Gastroenterology, vol. 102, no. 4, pp. 794–802, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. D. K. Zhang, L. N. Cheng, X. L. Huang, W. Shi, J. Y. Xiang, and H. T. Gan, “Tetrandrine ameliorates dextran-sulfate-sodium-induced colitis in mice through inhibition of nuclear factor-κB activation,” International Journal of Colorectal Disease, vol. 24, no. 1, pp. 5–12, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. T. Ishihara, K. I. Tanaka, Y. Tasaka et al., “Therapeutic effect of lecithinized superoxide dismutase against colitis,” Journal of Pharmacology and Experimental Therapeutics, vol. 328, no. 1, pp. 152–164, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. Y. H. Zhou, J. P. Yu, Y. F. Liu et al., “Effects of Ginkgo biloba extract on inflammatory mediators (SOD, MDA, TNF-α, NF-κBp65, IL-6) in TNBS-induced colitis in rats,” Mediators of Inflammation, vol. 2006, Article ID 92642, 9 pages, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. X. C. Liu, Q. Mei, J. M. Xu, and J. Hu, “Balsalazine decreases intestinal mucosal permeability of dextran sulfate sodium-induced colitis in mice,” Acta Pharmacologica Sinica, vol. 30, no. 7, pp. 987–993, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. E. B. Kurutas, A. Cetinkaya, E. Bulbuloglu, and B. Kantarceken, “Effects of antioxidant therapy on leukocyte myeloperoxidase and Cu/Zn-superoxide dismutase and plasma malondialdehyde levels in experimental colitis,” Mediators of Inflammation, vol. 2005, no. 6, pp. 390–394, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. L. N. Liu, Q. B. Mei, L. Liu et al., “Protective effects of Rheum tanguticum polysaccharide against hydrogen peroxide-induced intestinal epithelial cell injury,” World Journal of Gastroenterology, vol. 11, no. 10, pp. 1503–1507, 2005. View at Google Scholar · View at Scopus
  62. I. Fridovich, “Oxygen radicals, hydrogen peroxide,and oxygen toxicity,” in Free Radicals in Biology, W. A. Pryor, Ed., pp. 239–277, Academic Press, New York, NY, USA, 1976. View at Google Scholar
  63. Y. Suzuki, T. Matsumoto, S. Okamoto, and T. Hibi, “A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis,” Colorectal Disease, vol. 10, no. 9, pp. 931–934, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. K. Uchimura, A. Nagasaka, R. Hayashi et al., “Changes in superoxide dismutase activities and concentrations and myeloperoxidase activities in leukocytes from patients with diabetes mellitus,” Journal of Diabetes and its Complications, vol. 13, no. 5-6, pp. 264–270, 1999. View at Publisher · View at Google Scholar · View at Scopus